Hypoxia Treatment Market Size
| Study Period | 2019 - 2029 |
| Base Year For Estimation | 2023 |
| CAGR | 3.50 % |
| Fastest Growing Market | North America |
| Largest Market | Asia-Pacific |
| Market Concentration | High |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
Hypoxia Treatment Market Analysis
The Hypoxia Treatment Market is expected to grow at a registered CAGR of 3.5% during the forecast period.
Coronavirus disease-2019 (COVID-19) produces severe hypoxemia, exacerbating the COVID-19 damage. Furthermore, the precise impact of hypoxia on COVID-19 patients is uncertain. Early on in the COVID-19 infection, some COVID-19 patients develop a condition known as "silent hypoxia," and it has been observed that hypoxia may aggravate the infection and exacerbate lung cell destruction. According to the study titled "Silent Hypoxia in Coronavirus disease-2019: Is it more dangerous? A retrospective cohort study" published in the Lung India in June 2022, around 32% to 65% of COVID-19 patients developed silent hypoxia. Additionally, according to the study titled "Oxygen therapy strategies and techniques to treat hypoxia in COVID-19 patients" published in the European Review of Medical and Pharmaceutical Science, in May 2020, early-stage oxygen therapy has the potential to treat hypoxia in COVID-19 patients As a result, the market growth is expected to impact by the rise in demand for oxygen therapy among COVID-19 patients.
The market is being driven by both an increase in research and development activity by the pharmaceutical industry and an increase in the prevalence of hypoxia. According to the study titled "The prevalence of hypoxemia among pediatric and adult patients presenting to healthcare facilities in low- and middle-income countries: protocol for a systematic review and meta-analysis" published in the Systematic Review in March 2020, the prevalence of hypoxemia in children under the age of 12 ranged from 2-23% in the low and middle incomes countries. Therefore, the increasing prevalence of hypoxia is anticipated to increase the demand for therapeutic options in the management of diseases, driving up the market's growth.
Additionally, rising R&D activity is anticipated to support market expansion over the forecast period. According to the study titled "Helmet CPAP to treat hypoxic pneumonia outside the ICU: an observational study " published in the Critical Care in February 2021, an efficient interface for administering noninvasive continuous positive airway pressure (CPAP) is a helmet. Patients might profit from helmet CPAP as a life-saving treatment to increase survival. Moreover, growing research and development spending is expected to boost the market growth. As per the September 2020 update by the Pharmaceutical Research and Manufacturers of America (PhRMA), the PhRMA members had invested nearly USD 83 billion in R&D activities in 2020. Furthermore, as per the same source, more than 260 vaccines are in the pipeline by biopharmaceutical companies for various diseases, including COVID-19, as per PhRMA, 2020.
Thus, all aforementioned factors such as the rising prevalence of hypoxia and growing research and development activity expected to boost the market growth. However, stringent government regulation coupled with the availability of substitute products may restrain the market growth over the forecast period.
Hypoxia Treatment Market Trends
This section covers the major market trends shaping the Hypoxia Treatment Market according to our research experts:
Asthma are Expected to Witness Healthy Growth Over the Forecast Period
Asthma is one of the most widespread illnesses in the world and a potentially fatal condition that impairs patients' ability to breathe normally. It is a chronic condition that tightens and stretches the lungs' airways, leading to recurrent episodes of shortness of breath, bronchospasm, and reversible airflow obstruction. In addition, there has been a significant increase in cigarette use, which aggravates asthma symptoms. Additionally, as industrialization has grown, so has the number of asthma cases, which could increase the demand for asthma medications in the future. The segment growth is anticipated to be boosted by the rising number of asthma cases. The substantial increase in prevalence and incidence of asthma has led to an increase in the patient population, which has, in turn, increased the demand for these drugs. According to the World Health Organization (WHO) 2021 factsheet, asthma is a major non-communicable disease (NCD), affecting both children and adults. Globally, it affected an estimated 262 million people in 2020 and caused 461,000 deaths.
Furthermore, increasing research and development activity and product launches by the market players are likely to boost the growth of the market. For instance, in March 2021, GlaxoSmithKline PC, in collaboration with IQVIA Pty Ltd, initiated a Phase III clinical trial to evaluate the efficacy and safety of GSK3511294 (Depemokimab) in adult and adolescent patients with severe uncontrolled asthma. The trial is expected to be completed in October 2023. Similarly, in February 2021, AstraZeneca PLC, in collaboration with Amgen Inc., initiated a Phase I clinical trial to evaluate the pharmacokinetic (PK) profile of a single subcutaneous (SC) dose of tezepelumab in children aged 5 to 11 years with asthma. The trial is expected to be completed in September 2021. Thus, the aforementioned factors are expected to drive segment growth over the forecast period.
Thus, all aforementioned factors such as the rising prevalence of hypoxia in asthmatic patients expected to boost the market growth over the forecast period.
North America is Expected to Hold a Significant Market Share Over the Forecast Period
North America dominates the global market for hypoxia because of the prevalence of hypoxia, rising research and development spending, and rising personal disposable income. hypoxia is majorly associated with respiratory diseases such as asthma, COPD, and Pneumonia and thus the rising incidence of conditions like COPD and asthma contributes to the market's expansion. For instance, according to the National, Heart, Lung, and Blood Institutes updates in March 2022, more than 15 million persons in the United States suffer from COPD each year. The fourth-leading cause of death in the United States was COPD, which is a significant cause of impairment.
Moreover, as per Asthma Canada Annual Report 2021, every day, an estimated 317 Canadians are diagnosed with asthma. Every year, asthma attacks cause over 70,000 hospitalizations. Asthma is the third most common chronic disease in Canada, affecting more than 3.8 million Canadians each year. The high number of patients affected by asthma and COPD increases the demand for drugs for the treatment of the target disease, thereby boosting the growth of this region.
Moreover, growing research and development activity by various institutes likely to propel the growth of the market is expected to witness high growth. For instance, in August 2022, Pgharmazz Inc (United States) received clearance for investigational drug application from the Central Drug Control Organization to conduct phase II clinical trials for Sovateltide in the condition of hypoxic ischemia. Additionally, in January 2022, OxiWear, the first non-intrusive wearable for medical-grade, continuous oxygen monitoring, raised USD 1.25 million in funding.
Thus, all above-mentioned factors are expected to boost the market over the forecast period.
Hypoxia Treatment Industry Overview
The market studied is a consolidated market owing to the presence of few major market players. With the rising technological advancements and product innovations, mid-size and small-scale companies are increasing their market presence by introducing new devices into the market at competitive prices. Some of the market players are Thermo Fisher Scientific Inc., Resmed, Hamilton Medical, Merck KGaA, Spotlight Labs, LLC., HypOxygen, PharmaShots, Hancock Medical Inc. etc.
Hypoxia Treatment Market Leaders
Merck KGaA
Koninklijke Philips NV
Fisher & Paykel Healthcare Limited
Resmed
Hamilton Company
*Disclaimer: Major Players sorted in no particular order
Hypoxia Treatment Market News
- In April 2022, CAIRE The LifeStyle portable oxygen concentrator was introduced, vastly enhancing the quality of life for oxygen users all over the world.
- In May 2022, Max ventilator has launched the multifunctional noninvasive ventilators which come with the inbuild oxygen therapy and humidifier.
Hypoxia Treatment Market Report - Table of Contents
1. INTRODUCTION
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Growing Prevalence of Hypoxia
4.2.2 Increasing Research and Development Activity
4.3 Market Restraints
4.3.1 Stringent Government Regulation Coupled with Availability of Substitute Product
4.4 Porter's Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION (Market Size by Value - USD million)
5.1 By Type
5.1.1 Hypoxic Hypoxia
5.1.2 Anaemic Hypoxia
5.1.3 Stagnant Hypoxia
5.1.4 Histotoxic Hypoxia
5.2 By Diseases Type
5.2.1 Chronic Obstructive Pulmonary Disease (COPD)
5.2.2 Pneumonia
5.2.3 Asthma
5.2.4 Others
5.3 By End User
5.3.1 Hospitals/Clinics
5.3.2 Others
5.4 Geography
5.4.1 North America
5.4.2 Europe
5.4.3 Asia-Pacific
5.4.4 Middle East and Africa
5.4.5 South America
6. COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Thermo Fisher Scientific Inc.
6.1.2 Resmed
6.1.3 Merck KGaA
6.1.4 Spotlight Labs, LLC.
6.1.5 HypOxygen
6.1.6 Hancock Medical Inc.
6.1.7 Fisher & Paykel Healthcare Limited
6.1.8 Invacare Corporation
6.1.9 Natus Medical Incorporated
6.1.10 Getinge AB
6.1.11 Hamilton Company
6.1.12 Koninklijke Philips NV
- *List Not Exhaustive
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
Hypoxia Treatment Industry Segmentation
Hypoxia is a condition in which the body's tissues do not have access to enough oxygen to maintain healthy homeostasis. This can be caused by either insufficient blood flow to the tissues or low blood oxygen levels (hypoxemia). Acute, chronic, or acute and chronic forms of hypoxia can be present and range in severity from mild to severe. The Hypoxia Treatment Market is Segmented By Type (Hypoxic Hypoxia, Anaemic Hypoxia, Stagnant Hypoxia, and Histotoxic Hypoxia), Disease Type (Chronic Obstructive Pulmonary Disease (COPD), Pneumonia, Sleep, Asthma, and Others), End User (Hospitals/Clinics and Others) and Geography (North America, Europe, Asia-Pacific, Middle East, and Africa, South America). The report offers the value (in USD million) for the above segments.
| By Type | |
| Hypoxic Hypoxia | |
| Anaemic Hypoxia | |
| Stagnant Hypoxia | |
| Histotoxic Hypoxia |
| By Diseases Type | |
| Chronic Obstructive Pulmonary Disease (COPD) | |
| Pneumonia | |
| Asthma | |
| Others |
| By End User | |
| Hospitals/Clinics | |
| Others |
| Geography | |
| North America | |
| Europe | |
| Asia-Pacific | |
| Middle East and Africa | |
| South America |
Hypoxia Treatment Market Research FAQs
What is the current Global Hypoxia Treatment Market size?
The Global Hypoxia Treatment Market is projected to register a CAGR of 3.5% during the forecast period (2024-2029)
Who are the key players in Global Hypoxia Treatment Market?
Merck KGaA , Koninklijke Philips NV, Fisher & Paykel Healthcare Limited, Resmed and Hamilton Company are the major companies operating in the Global Hypoxia Treatment Market.
Which is the fastest growing region in Global Hypoxia Treatment Market?
North America is estimated to grow at the highest CAGR over the forecast period (2024-2029).
Which region has the biggest share in Global Hypoxia Treatment Market?
In 2024, the Asia-Pacific accounts for the largest market share in Global Hypoxia Treatment Market.
What years does this Global Hypoxia Treatment Market cover?
The report covers the Global Hypoxia Treatment Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Global Hypoxia Treatment Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
Global Hypoxia Treatment Industry Report
Statistics for the 2024 Global Hypoxia Treatment market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Global Hypoxia Treatment analysis includes a market forecast outlook to 2029 and historical overview. Get a sample of this industry analysis as a free report PDF download.
